Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers.
暂无分享,去创建一个
T. Julian | N. Wolmark | L. Gu | J. Silverman | S. Shackney | L. Janocko | K. Brown | C. A. Smith | A. Pollice | S. Singh | L. Sweeney | C. A. Smith
[1] K. Leslie,et al. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. , 1990, Archives of pathology & laboratory medicine.
[2] J F Silverman,et al. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] R. Hruban,et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.
[4] D. Horsfall,et al. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. , 1986, British Journal of Cancer.
[5] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[6] G. Riou,et al. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. , 1988, Oncogene research.
[7] T. Kiyono,et al. The G2 Checkpoint Is Maintained by Redundant Pathways , 1999, Molecular and Cellular Biology.
[8] A. Wyllie,et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. , 1995, British Journal of Cancer.
[9] Patrick E Carroll,et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.
[10] T. Ried,et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability , 1998, Oncogene.
[11] G. Woude,et al. Abnormal Centrosome Amplification in the Absence of p53 , 1996, Science.
[12] S. Hellman,et al. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. , 2000, Cancer research.
[13] R. Zeillinger,et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.
[14] R. Hartsock,et al. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. , 1992, Cytometry.
[15] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[16] Carissa A. Sanchez,et al. Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.
[17] G. Wahl,et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.
[18] Carissa A. Sanchez,et al. A p53-dependent mouse spindle checkpoint , 1995, Science.
[19] E Gabrielson,et al. Genetic divergence in the clonal evolution of breast cancer. , 1996, Cancer research.
[20] P. Gariglio,et al. In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. , 1988, Journal of the National Cancer Institute.
[21] Carissa A. Sanchez,et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. , 1994, Cancer research.
[22] J. Bartek,et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro , 1990, International journal of cancer.
[23] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[24] R. Lidereau,et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Benchimol,et al. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. , 1993, The EMBO journal.
[26] L. Medeiros,et al. Differential expression of cyclin D1 in breast papillary carcinomas and benign papillomas: an immunohistochemical study. , 1999, Archives of pathology & laboratory medicine.
[27] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[28] L. Strong,et al. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. , 1990, Cancer research.
[29] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[30] A. C. Carter,et al. Steroid hormone receptor immunohistochemistry and amplification of c‐myc protooncogene relationship to disease‐free survival in breast cancer , 1993, Cancer.
[31] J. Nesland,et al. Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas. , 1999, Acta oncologica.
[32] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[33] D. Lane,et al. The p53 tumour suppressor gene , 1998, The British journal of surgery.
[34] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[35] P. Carroll,et al. Genetic alterations in primary bladder cancers and their metastases. , 1998, Cancer research.
[36] D. Horsfall,et al. The significance of oncogene amplification in primary breast cancer , 1989, International journal of cancer.
[37] C. Paraskeva,et al. Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. , 1995, Oncogene.
[38] S. Shackney,et al. Model for the genetic evolution of human solid tumors. , 1989, Cancer research.
[39] L. Norton,et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. V. van Diest,et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.
[41] E. Prochownik,et al. C-myc overexpression and p53 loss cooperate to promote genomic instability , 1999, Oncogene.
[42] W. J. Brammar,et al. Oncogene organisation and expression: prediction in breast cancer. , 1989, Hormone research.
[43] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] W. J. Brammar,et al. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. , 1991, Oncogene.
[45] K. Kinzler,et al. Genetic instability in colorectal cancers , 1997, Nature.
[46] G. Stark,et al. MYC Abrogates p53-Mediated Cell Cycle Arrest in N-(Phosphonacetyl)-l-Aspartate-Treated Cells, Permitting CAD Gene Amplification , 1998, Molecular and Cellular Biology.
[47] I. Ellis,et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.
[48] A. Feinberg,et al. Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression , 1995, Nature Medicine.
[49] X. Chen,et al. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.
[50] R. Hartsock,et al. Discrepancies between flow cytometric and cytogenetic studies in the detection of aneuploidy in human solid tumors. , 1990, Cytometry.
[51] D. Carney,et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.
[52] Rochelle L. Garcia,et al. C‐ERBB‐2 oncogens protein in In situ and invasive lobular breast neoplasia , 1991 .
[53] Jiri Bartek,et al. Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.
[54] C. Purdie,et al. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. , 1993, Oncogene.
[55] E. Schröck,et al. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.
[56] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[57] D. Persons,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[58] T. Shankey,et al. Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.
[59] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[60] J. Cunningham,et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.
[61] S. Shackney,et al. Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture. , 1989, Cancer research.
[62] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[63] Carissa A. Sanchez,et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[64] T. Oyama,et al. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. , 1998, Cancer research.
[65] A. Levine,et al. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.